Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III

This study has been completed.
Information provided by:
French Innovative Leukemia Organisation Identifier:
First received: June 5, 2007
Last updated: NA
Last verified: June 2007
History: No changes posted

Improved outcome of high risk lymphoblastic leukemia (ALL) with laite high dose therapy.

High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma (LBL).

Condition Intervention Phase
Leukemia, Lymphocytic, Acute
Drug: interferon alpha 2a
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III

Resource links provided by NLM:

Further study details as provided by French Innovative Leukemia Organisation:

Primary Outcome Measures:
  • overall survival [ Time Frame: time to death ]

Secondary Outcome Measures:
  • Efficacy of study treatments [ Time Frame: time to end of treatment ]

Enrollment: 232
Study Start Date: September 1994
Study Completion Date: April 2002
Detailed Description:
Comparison between two autograf therapeutic strategies in high risk patients Ramdomised comparison between maintenance treatment with or not interferon alpha 2 a

Ages Eligible for Study:   15 Years to 65 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • ALL high risk or low risk or lymphoblastic lymphoma
  • age 15-55 years old
  • informed consent signed

Exclusion Criteria:

  • patients previously treated with a chemotherapy or alpha-interferon
  • ALL 3 (burkitt like)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00483132

INorbert IFRAH
Angers, chu ANGERS, France, 49000
Sponsors and Collaborators
French Innovative Leukemia Organisation
Principal Investigator: Norbert IFRAH, Pr French Innovative Leukemia Organisation
Principal Investigator: Noël MILPIED French Innovative Leukemia Organisation
  More Information

Publications: Identifier: NCT00483132     History of Changes
Other Study ID Numbers: GOELAL02 
Study First Received: June 5, 2007
Last Updated: June 5, 2007
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on October 26, 2016